Biovica International AB (publ) - Asset Resilience Ratio

Latest as of July 2025: 28.69%

Biovica International AB (publ) (BIOVIC-B) has an Asset Resilience Ratio of 28.69% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Biovica International AB (publ) strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr16.30 Million
≈ $1.75 Million USD Cash + Short-term Investments

Total Assets

Skr56.82 Million
≈ $6.11 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Biovica International AB (publ)'s Asset Resilience Ratio has changed over time. See net asset quality index of Biovica International AB (publ) to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Biovica International AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Biovica International AB (publ) worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr16.30 Million 28.69%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr16.30 Million 28.69%

Asset Resilience Insights

  • Very High Liquidity: Biovica International AB (publ) maintains exceptional liquid asset reserves at 28.69% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Biovica International AB (publ) Industry Peers by Asset Resilience Ratio

Compare Biovica International AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Biovica International AB (publ) (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Biovica International AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-04-30 0.00% Skr0.00
≈ $0.00
Skr64.95 Million
≈ $6.99 Million
--
2024-04-30 19.55% Skr25.68 Million
≈ $2.76 Million
Skr131.41 Million
≈ $14.14 Million
+5.38pp
2023-04-30 14.17% Skr24.41 Million
≈ $2.63 Million
Skr172.29 Million
≈ $18.54 Million
-53.21pp
2022-04-30 67.38% Skr102.17 Million
≈ $11.00 Million
Skr151.63 Million
≈ $16.32 Million
-8.08pp
2021-04-30 75.46% Skr145.38 Million
≈ $15.64 Million
Skr192.65 Million
≈ $20.73 Million
+30.27pp
2020-04-30 45.19% Skr40.79 Million
≈ $4.39 Million
Skr90.26 Million
≈ $9.71 Million
-2.07pp
2019-04-30 47.26% Skr28.76 Million
≈ $3.10 Million
Skr60.86 Million
≈ $6.55 Million
-4.89pp
2018-04-30 52.16% Skr42.13 Million
≈ $4.53 Million
Skr80.77 Million
≈ $8.69 Million
-15.21pp
2017-04-30 67.37% Skr65.47 Million
≈ $7.05 Million
Skr97.18 Million
≈ $10.46 Million
+67.43pp
2016-04-30 -0.07% Skr-19.81K
≈ $-2.13K
Skr28.73 Million
≈ $3.09 Million
--
pp = percentage points

About Biovica International AB (publ)

ST:BIOVIC-B Sweden Biotechnology
Market Cap
$12.41 Million
Skr115.35 Million SEK
Market Cap Rank
#26502 Global
#572 in Sweden
Share Price
Skr0.42
Change (1 day)
+14.79%
52-Week Range
Skr0.28 - Skr0.84
All Time High
Skr66.10
About

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more